HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium.

Abstract
Following a four-day control period during which an elevated serum calcium level either stabilized or continued to rise despite maximally tolerated saline diuresis, 12 patients with neoplastic hypercalcemia were treated with intravenous etidronate disodium (etidronate) 7.5 mg/kg/day for up to seven days. Serum calcium reverted to normal levels in all patients, with the mean pretreatment serum calcium level of 12.5 +/- 0.4 mg/dl dropping to 9.2 +/- 0.2 mg/dl (p less than 0.01) by Day 7. Elevated urinary calcium (1,107 +/- 134 mg/g creatinine) and hydroxyproline levels (154 +/- 16 mg/g creatinine) declined to 245 +/- 52 mg/g creatinine and 75 +/- 14 mg/g creatinine, respectively, suggesting a marked reduction in bone resorption following treatment. Serum phosphorus levels were unchanged, but urinary phosphorus levels dropped rapidly from 1,181 +/- 125 mg/g creatinine before treatment to 723 +/- 94 mg/g creatinine after two days. Serum parathyroid hormone levels (mid-molecule assay) were suppressed before treatment (64 +/- 16 pg/ml), but rose rapidly to 223 +/- 68 pg/ml by Day 7 of treatment. The value of serum 1,25-dihydroxyvitamin D was initially below normal (16 +/- 3 pg/ml), but rose rapidly with treatment to 42 +/- 12 pg/ml by Day 7. Symptoms of hypercalcemia and bone pain improved with treatment, and no serious adverse reactions to treatment were encountered. Intravenous etidronate is apparently an effective and safe treatment for neoplastic hypercalcemia.
AuthorsT P Jacobs, A C Gordon, S J Silverberg, E Shane, L Reich, T L Clemens, C M Gundberg
JournalThe American journal of medicine (Am J Med) Vol. 82 Issue 2A Pg. 42-50 (Feb 23 1987) ISSN: 0002-9343 [Print] United States
PMID3030098 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Parathyroid Hormone
  • Phosphorus
  • Creatinine
  • Cyclic AMP
  • Calcitriol
  • Etidronic Acid
  • Calcifediol
  • Hydroxyproline
  • Calcium
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Calcifediol (blood)
  • Calcitriol (blood)
  • Calcium (metabolism)
  • Creatinine (urine)
  • Cyclic AMP (urine)
  • Etidronic Acid (therapeutic use)
  • Female
  • Humans
  • Hydroxyproline (urine)
  • Hypercalcemia (drug therapy, etiology)
  • Infusions, Intravenous
  • Male
  • Paraneoplastic Endocrine Syndromes (drug therapy)
  • Parathyroid Hormone (blood)
  • Phosphorus (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: